Received Dec 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
first Shingrix vaccine in June of 2024 and the second Shingrix vaccine in October 2025; Shivers; Shaking; general flu-like symptoms; Weaknesses; This non-serious case was reported by a consumer via call center representative and described the occurrence of shivers in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of no adverse event (1st dose received in JUN-2024 and experienced no side effects). In OCT-2025, the patient received the 2nd dose of Shingrix. In OCT-2025, 12 hrs after receiving Shingrix, the patient experienced shivers (Verbatim: Shivers), tremor (Verbatim: Shaking), influenza-like symptoms (Verbatim: general flu-like symptoms), weakness (Verbatim: Weaknesses) and drug dose administration interval too long (Verbatim: first Shingrix vaccine in June of 2024 and the second Shingrix vaccine in October 2025). The outcome of the shivers, tremor, influenza-like symptoms and weakness were resolved (duration 1 day) and the outcome of the drug dose administration interval too long was not applicable. It was unknown if the reporter considered the shivers, tremor, influenza-like symptoms and weakness to be related to Shingrix. It was unknown if the company considered the shivers, tremor, influenza-like symptoms and weakness to be related to Shingrix. Additional Information: GSK Receipt Date: 08-DEC-2025 The patient self-reported this case for herself. The inappropriate schedule of vaccine administration was due to insurance changes. The symptoms were resolved in 2025. The batch number was not provided, and unable to contact the reporter.